- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04335266
A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects
April 2, 2020 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Randomized, Open, Single-center, Two-cycle, Double-sequence Crossover Study to Investigate the Effects of a High-fat Diet on the Pharmacokinetics of Healthy Chinese Male Adult Subjects After Oral Administration of SHR2554 Tablets
The primary objective of the study is to evaluate the effect of high-fat diet on pharmacokinetics of healthy Chinese male adult subjects after oral administration of SHR2554 tablets.
The secondary objective of the study is to evaluate the safety of single dose of SHR2554 orally in healthy subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Henan, China
- Henan Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 60 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male subjects aged 40~60 at the date of signing the informed consent;
- Male body weight ≥ 50kg , body mass index (BMI) within the range of 19 ~ 28kg /m2 (including 19 and 28) (BMI= weight (kg)/height 2 (m2));
- During screening period physical examination, vital signs, blood routine, urine routine, blood biochemistry, coagulation, abdominal ultrasound, chest X-ray and other examination results must be within the normal range consistent with age and gender, or in accordance with the protocol, or judged to be "no clinical significance (NCS)" if beyond the normal range;
- Agree to abstain from sex or use effective non-drug contraceptives from screening to at least 3 months after the last study drug administration (female subjects are also required to abstain or use effective non-drug contraceptives two weeks prior to study entry);
- The subject can communicate well with the researcher, understand and comply with the requirements of the study, understand and sign the informed consent.
Exclusion Criteria:
- Allergic constitution or known allergy to the research drug/similar drugs;
- Frequent use of sedatives, sleeping pills or other addictive drugs; History of drug abuse within 6 months prior to first administration or drug abuse screening positive; Alcoholic or often drinkers within 6 months prior to screening, the average drinking amount is more than 14 units a week (1 unit= 285 ml beer or 25 ml alcohol content of 40% spirits or 100 ml wine), a heavy smoker or quitting time less than 3 months, alcohol breath test positive and nicotine test positive, and can't quit smoking and alcohol during the study;
- A history of cardiovascular diseases such as myocarditis, coronary heart disease, pathological arrhythmia and stroke;
- Pulmonary diseases, including invasive lung disease, pneumonia, and dyspnoea;
- Chronic kidney disease, renal insufficiency, renal anaemia;
- A history of dysphagia or any gastrointestinal disease affecting drug absorption;
- Any uncontrolled peptic ulcer, colitis, pancreatitis, etc;
- Any operation within the previous 3 months that may affect the absorption, distribution, metabolism and excretion of drugs;
- Previous medical history of cardiovascular, liver, kidney, lung, digestive tract, nervous system diseases, etc., which may significantly affect the absorption, distribution, metabolism and excretion of drugs, or may pose a hazard to the subjects participating in the study. The following medical history or conditions should be considered: inflammatory gastroenteritis, gastroesophageal reflux, gastrointestinal or rectal bleeding; History of pancreatic injury or pancreatitis; Greater surgical history such as gastrectomy, gastroenterostomy, or enterectomy; History of acute and chronic renal insufficiency, history of renal transplantation;
- Taking any hepatotoxic drugs (such as dapsone, erythromycin, fluconazole, ketoconazole and rifampicin) in the months prior to screening;
- hose who have participated in other clinical trials and taken the research drugs within 3 months before the first drug administration;
- Any drug that altered the activity of liver enzymes was given 28 days prior to administration or during the study;
- Use any prescription drug or herbal tonic within one week before the first dose;
- Use any over-the-counter (OTC) or food supplement (including vitamins, calcium tablets, etc.) within one weeks before the first dose;
- Clinical laboratory examination is abnormal and to be CS;
- Hepatitis B surface antigen positive, hepatitis C2 antibody positive, syphilis antibody positive, HIV antibody positive;
- Subjects refused to stop using any beverage or food containing methyl xanthine, such as coffee, tea, cola, chocolate, etc. from 48 hours before the first administration until the end of the study;
- Blood donation within 3 months before the screening or blood loss great than 400 mL;
- Difficulty in venous blood collection or inability to tolerate venepuncture;
- Other factors (including but not limited to inability to understand the requirements of the study, poor compliance, physical weakness, etc.) that are not suitable for participating in the study, as judged by the researcher.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment group A
Drug: SHR2554 fasted in P1, high-fat diet in P2 SHR2554 administration in fasted condition in period 1, SHR2554 administration after high-fat diet in period 2
|
SHR2554
|
EXPERIMENTAL: Treatment group B
Drug: SHR2554 high-fat diet in P1, fasted in P2 SHR2554 administration after high-fat diet in period 1, SHR2554 administration in fasted condition in period 2
|
SHR2554
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics parameter: Cmax of SHR2554
Time Frame: Day 1 and Day 8 of the single dose
|
Peak Plasma Concentration (Cmax) of SHR2554
|
Day 1 and Day 8 of the single dose
|
Pharmacokinetics parameter: AUC of SHR2554
Time Frame: Day 1 and Day 8 of the single dose
|
Area under the plasma concentration versus time curve (AUC) of SHR2554
|
Day 1 and Day 8 of the single dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 6, 2019
Primary Completion (ACTUAL)
September 9, 2019
Study Completion (ACTUAL)
March 30, 2020
Study Registration Dates
First Submitted
April 1, 2020
First Submitted That Met QC Criteria
April 2, 2020
First Posted (ACTUAL)
April 6, 2020
Study Record Updates
Last Update Posted (ACTUAL)
April 6, 2020
Last Update Submitted That Met QC Criteria
April 2, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- SHR2554-I-103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Adult Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
China Resources Biopharmaceutical Co., LtdPeking University Third HospitalRecruiting
-
Auzone Biological Technology Pty LtdCompleted
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy Adult SubjectsJapan
-
Alvotech Swiss AGIqvia Pty LtdCompletedHealthy Adult SubjectsNew Zealand, United Kingdom
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Connect Biopharma Australia Pty LtdCompletedHealthy Adult SubjectsAustralia
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult SubjectsChina
Clinical Trials on SHR2554
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPeripheral T-cell Lymphoma
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRelapsed/Refractory PTCLT With at Least One Line of Prior Systemic TherapyChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingFollicular LymphomaChina
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedProstate Cancer | Castration-resistant Prostate CancerChina
-
Chinese PLA General HospitalRecruitingRelapsed or Refractory Hodgkin LymphomaChina
-
Chinese PLA General HospitalRecruitingLymphoma | Solid TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Peking University Cancer Hospital & InstituteRecruitingRelapsed or Refractory Mature Lymphoid NeoplasmsChina